Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Sponsor: Summit Therapeutics

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05899608

Patient View

This Phase 3 study evaluates ivonescimab with chemotherapy versus pembrolizumab with chemotherapy for metastatic squamous NSCLC. Eligible participants are adults with ECOG 0-1, Stage IV squamous NSCLC, and no prior systemic treatment. Interventions include IV injections of ivonescimab or pembrolizumab combined with chemotherapy. Primary endpoint is overall survival.

Patient Parameters

Program Overview

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years old at the time of enrollment
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Expected life expectancy ≥ 3 months
  • Metastatic (Stage IV) NSCLC
  • Histologically or cytologically confirmed squamous or non-squamous NSCLC
  • Recorded measurement of the Tumor Proportion Score (TPS) for PD-L1 expression, irrespective of the PD-L1 expression, prior to randomization
  • At least one measurable noncerebral lesion according to RECIST 1.1
  • No prior systemic treatment for metastatic NSCLC

Exclusion Criteria

  • Histologic or cytopathologic evidence of the presence of small cell lung carcinoma

  • Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which first-line approved therapies are available.

    • For non-squamous histology patients, actionable driver mutation testing results are required before randomization.

  • Has received any prior therapy for NSCLC in the metastatic setting

  • Tumor invasion, encasement of organs (e.g. heart, trachea, esophagus, central bronchi), or major blood vessels (e.g aorta, central veins), if poses a significant increased risk of bleeding.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.